Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 2/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.37 |
| ▸ | NNMT | P40261 | 1/20 | 0.36 |
| ▸ | MKNK2 | Q9HBH9 | 6/20 | 0.36 |
| ▸ | UBA6 | A0AVT1 | 4/20 | 0.34 |
| ▸ | NAE1 | Q13564 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | GRK5 | P34947 | 1/20 | 0.34 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.34 |
| ▸ | NEDD8 | Q15843 | 1/20 | 0.34 |
| ▸ | UBA3 | Q8TBC4 | 1/20 | 0.34 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.34 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.33 |
| ▸ | AHCY | P23526 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14563559 | 0.83 | NAE1 (0.39) | PRMT5WDR77NNMTMKNK2UBA6 | |
| SCHEMBL937900 | 0.82 | MKNK2 (0.37) | PRMT5WDR77NNMTMKNK2UBA6 | |
| SCHEMBL937901 | 0.82 | UBA6 (0.49) | PRMT5WDR77NNMTMKNK2UBA6 | |
| SCHEMBL14563561 | 0.81 | NAE1 (0.53) | UBA6NAE1CA2GRK5CSNK1A1 | |
| SCHEMBL25049095 | 0.78 | PRMT5 (0.36) | PRMT5WDR77NNMTMKNK2 | |
| SCHEMBL20916985 | 0.76 | PRMT5 (0.45) | PRMT5WDR77 | |
| SCHEMBL19563037 | 0.76 | ADK (0.48) | PRMT5WDR77AHCYADORA2B | |
| SCHEMBL191943 | 0.76 | ADK (0.48) | PRMT5WDR77AHCYADORA2B | |
| SCHEMBL1947419 | 0.76 | UBA6 (0.41) | TK1PRMT5WDR77NNMTUBA6 | |
| SCHEMBL25048671 | 0.76 | UBA6 (0.42) | PRMT5WDR77UBA6NAE1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10745404-B2 | Process for the synthesis of E1 activating enzyme inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2020-08-18 | — | — | US | disclosed |
| EP-2546256-B1 | Process for the synthesis of E1 activating enzyme inhibitors | MILLENNIUM PHARM INC (US) | 2019-10-09 | — | — | EP | disclosed |
| EP-2540726-B1 | Intermediates for the synthesis of E1 activity activating enzyme inhibitors | MILLENNIUM PHARM INC (US) | 2019-10-09 | — | — | EP | disclosed |
| EP-2540727-B1 | SULFAMOYLATING REAGENT | MILLENNIUM PHARM INC (US) | 2018-07-25 | — | — | EP | disclosed |
| US-20180079755-A1 | PROCESS FOR THE SYNTHESIS OF E1 ACTIVATING ENZYME INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-22 | — | — | US | disclosed |
| US-9802938-B2 | Sulfamoylating reagents | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| EP-2178880-B1 | PROCESS FOR THE SYNTHESIS OF E1 ACTIVATING ENZYME INHIBITORS | MILLENNIUM PHARM INC (US) | 2017-10-04 | — | — | EP | disclosed |
| US-20150353555-A9 | PROCESS FOR THE SYNTHESIS OF E1 ACTIVATING ENZYME INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150080573-A1 | PROCESS FOR THE SYNTHESIS OF E1 ACTIVATING ENZYME INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-8933225-B2 | Process for the synthesis of E1 activating enzyme inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-01-13 | — | — | US | disclosed |
| EP-2546256-A2 | Process for the synthesis of intermediates compounds useful for the preparation of E1 activity activating enzyme inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-01-16 | — | — | EP | disclosed |
| EP-2540727-A1 | SULFAMOYLATING REAGENT | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-01-02 | — | — | EP | disclosed |
| EP-2540726-A1 | Intermediates for the synthesis of E1 activity activating enzyme inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-01-02 | — | — | EP | disclosed |
| US-20090036678-A1 | Process for the synthesis of E1 activating enzyme inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353555-A9 | PROCESS FOR THE SYNTHESIS OF E1 ACTIVATING ENZYME INHIBITORS | SULT1E1, SULT1A1, ALDH18A1 | TK1 270/4885PRMT5 525/4885WDR77 1507/4885 |
| US-10745404-B2 | Process for the synthesis of E1 activating enzyme inhibitors | SULT1E1, SULT1A1, STS | TK1 225/4885PRMT5 541/4885WDR77 1826/4885 |
| US-20090036678-A1 | Process for the synthesis of E1 activating enzyme inhibitors | SULT1E1, SULT1A1, ALDH18A1 | TK1 270/4885PRMT5 525/4885WDR77 1507/4885 |
| US-20150080573-A1 | PROCESS FOR THE SYNTHESIS OF E1 ACTIVATING ENZYME INHIBITORS | SULT1E1, SULT1A1, ALDH18A1 | TK1 270/4885PRMT5 525/4885WDR77 1507/4885 |
| US-20180079755-A1 | PROCESS FOR THE SYNTHESIS OF E1 ACTIVATING ENZYME INHIBITORS | SULT1E1, SULT1A1, ALDH18A1 | TK1 269/4885PRMT5 539/4885WDR77 1464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.